glp 1 and suicidal ideation Ozempic, Wegovy Under Investigation for Ideation, Hair Loss New study confirms GLP-1 medications

Treatment with tunicamycin (TM), an N-glycosylation inhibitor, in combination with gemcitabine significantly reduces the viability of PANC-1 cells, suggesting that targeting the N-glycosylation pathway holds promise for combination therapy in PDAC [157]

But new research from the University of Copenhagen might be able to change that

employers with corporate health plans found: 36% offer coverage for both diabetes and weight loss, compared to 34% in 2024 and just 26% in 2023

However, attention is drawn to the need for randomized, placebo and controlled clinical trials, with greater sampling to reach more solid conclusions